{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:45Z","timestamp":1792593645479,"version":"4.5.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early case reports and observational studies have suggested an association between isotretinoin and inflammatory bowel disease (IBD). However, large cohort studies and meta-analyses have not demonstrated a meaningful association between isotretinoin use and IBD development. Most prior research has focused on incident IBD risk, with limited attention to disease activity among patients with established IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective cohort study of patients with Crohn\u2019s disease (CD) or ulcerative colitis (UC) treated with isotretinoin between 2015 and 2025. Inclusion required at least 1 IBD assessment within the 4 months before and 12 months after isotretinoin initiation. Disease activity was assessed using Harvey\u2013Bradshaw Index (HBI), partial Mayo score (pMS), inflammatory biomarkers, and in some patients, intestinal ultrasound and fecal calprotectin. The primary outcome was composite IBD status change, defined as new clinical activity (\u0394\u2009\u2265\u20091 in HBI\/pMS), or isotretinoin discontinuation attributed to IBD activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-seven patients met inclusion criteria (57% CD, 43% UC). Most patients were in clinical remission at baseline (86%). Following isotretinoin exposure, 92% remained in remission, with no significant changes in HBI, pMS, erythrocyte sedimentation rate, C-reactive protein, or fecal calprotectin. IBD status change occurred in 4 patients (11%), with events largely attributable to underlying IBD-related factors, including biologic transitions, anti-drug antibody development, or medication dose adjustments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with established, well-controlled IBD, isotretinoin was not associated with clinically meaningful worsening of disease activity, supporting its use in carefully selected patients with stable disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag110","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:40:06Z","timestamp":1791027606000},"source":"Crossref","is-referenced-by-count":0,"title":["Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7855-8319","authenticated-orcid":false,"given":"Marley","family":"Cutrona","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Cices","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]},{"name":"Susan & Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5795","authenticated-orcid":false,"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan & Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]},{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology & Nutrition, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-1164","authenticated-orcid":false,"given":"Elizabeth A","family":"Spencer","sequence":"additional","affiliation":[{"name":"Susan & Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]},{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology & Nutrition, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026102109561495300_otag110-B1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40257-023-00765-9","article-title":"Isotretinoin exposure and risk of inflammatory bowel disease: a systematic review with meta-analysis and trial sequential analysis","volume":"24","author":"Yu","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026102109561495300_otag110-B2","first-page":"52","article-title":"Isotretinoin-induced inflammatory bowel disease","volume":"64","author":"Passier","year":"2006","journal-title":"Neth J Med"},{"key":"2026102109561495300_otag110-B3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1572-0241.2006.00632.x","article-title":"Possible association between isotretinoin and inflammatory bowel disease","volume":"101","author":"Reddy","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"2026102109561495300_otag110-B4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2013.1344","article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","volume":"149","author":"Etminan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026102109561495300_otag110-B5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaad.2022.05.024","article-title":"Impact of isotretinoin on inflammatory bowel disease flare in patients with preexisting inflammatory bowel disease diagnosis: a cross-sectional study","volume":"87","author":"Lopez","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026102109561495300_otag110-B6","author":"Association AAoD","year":"2025"},{"key":"2026102109561495300_otag110-B7","doi-asserted-by":"crossref","first-page":"1006.e1001","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026102109561495300_otag110-B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.14309\/ajg.0000000000003119","article-title":"Drug-induced acne in inflammatory bowel disease: a practical guide for the gastroenterologist","volume":"120","author":"Temido","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026102109561495300_otag110-B9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026102109561495300_otag110-B10","doi-asserted-by":"crossref","first-page":"otag036","DOI":"10.1093\/crocol\/otag036","article-title":"Prevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey","volume":"8","author":"Spencer","year":"2026","journal-title":"Crohns Colitis 360"},{"key":"2026102109561495300_otag110-B11","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2026102109561495300_otag110-B12","article-title":"Prevalence, age-distribution, and impact on management of acne in patients on upadacitinib for inflammatory bowel disease: insights from a single-center survey","author":"Spencer","year":"2025","journal-title":"Crohn\u2019s Colitis"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/4\/otag110\/71610674\/otag110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/4\/otag110\/71610674\/otag110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:56:18Z","timestamp":1792590978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag110\/8866644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag110","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"otag110"}}